Trinity Biotech
TRIB
35 hedge funds and large institutions have $20.2M invested in Trinity Biotech in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.3% less ownership
Funds ownership: 2.76% → 2.46% (-0.3%)
8% less funds holding
Funds holding: 38 → 35 (-3)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
46% less capital invested
Capital invested by funds: $37.3M → $20.2M (-$17.1M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
+$1.55M |
| 2 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$846K |
| 3 |
Renaissance Technologies
New York
|
+$171K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$56.4K |
| 5 |
FM
Fondren Management
Houston,
Texas
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
-$2.72M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$1.3M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$1.29M |
| 4 |
FWSM
First Wilshire Securities Management
Pasadena,
California
|
-$445K |
| 5 |
TA
Teton Advisors
Rye,
New York
|
-$371K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
US Bancorp
Minneapolis,
Minnesota
| $3K | -$10.1K | -852 | -67% |
|
27
Bank of America
Charlotte,
North Carolina
| $3K | -$737 | -62 | -16% |
|
|
JCM
28
Jacobi Capital Management
Pittston,
Pennsylvania
| $3K | – | – | – |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $2K | -$29.4K | -2,476 | -89% |
|
|
CIAS
30
Capital Investment Advisory Services
Raleigh,
North Carolina
| $2K | +$2.38K | +200 | New |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
32
UBS Group
Zurich,
Switzerland
| $1K | +$975 | +82 | New |
|
|
2L
33
22NW LP
Seattle,
Washington
| – | -$2.72M | -190,746 | Closed |
|
|
34
Boston Partners
Boston,
Massachusetts
| – | -$1.29M | -90,431 | Closed |
|
|
TA
35
Teton Advisors
Rye,
New York
| – | -$371K | -26,000 | Closed |
|
|
WAS
36
WESPAC Advisors SoCal
Pasadena,
California
| – | -$14K | -1,040 | Closed |
|
|
ECM
37
Engine Capital Management
New York
| – | -$12K | -859 | Closed |
|
|
LTFS
38
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$1K | -60 | Closed |
|
TRIB Hedge Fund Activity: Q2 2019 in Review
35 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2019, worth a combined $20.2M — down 46% from $37.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TRIB and 3 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 7 added.
The largest buyer was Stonehill Capital Management, adding an estimated $1.55M. The largest seller was 22NW LP, exiting entirely with an estimated $2.72M sold.
- 35 institutional investors held Trinity Biotech (TRIB) as of Q2 2019, down from 38 in Q1 2019.
- Funds reported $20.2M of Trinity Biotech stock for Q2 2019, down 46% quarter-over-quarter.
- 3 funds opened new Trinity Biotech positions in Q2 2019 and 6 closed out, a net change of -3 holders.
- The largest Trinity Biotech buyer in Q2 2019 was Stonehill Capital Management, an estimated $1.55M added.
- The largest Trinity Biotech seller in Q2 2019 was 22NW LP, an estimated $2.72M sold.
Based on aggregated 13F filings for Q2 2019.